WCS Consulting Inc.3190 Stirling Rd, Unit K4 ,Hollywood, FL 33021,

Hollywood,

FL,

US,

ZIP: 33021

Phone: 844-267-7299 | 954-947-5671  

Session Highlights

• Lessons learned from FDA’s DSCSA implementation and pilot
• What the next few years will look like for manufacturers, wholesalers and dispensers
• How to establish and implement a solid foundation and baseline for digital supply chain and the digital transformation process
• Strategic planning and realizing the return on investment and benefits
• Discuss some of the new technologies (e.g., Internet of Things) that will define categorically supply chain capabilities
• Ensure your company has the tools it needs to be at the forefront of this digital transformation of health information management and the drug supply chain

  ---

  
   

Overview

Passed in 2013, the Drug Supply Chain Security Act (DSCSA) gives the Federal Drug Administration (FDA) more control over the manufacturing of drugs in the United States. Starting in 2020, with full compliance by 2023, most pharmaceutical drugs now must be traced, verified, and serialized for the entire supply chain, from manufacturer to pharmacy. The supply chain regulatory deadline of 2023 will be here soon; however, now is the time for all industry stakeholders, manufacturers, wholesalers, distributors and dispensers, to take a step back and plan strategically. Now is the time to begin preparation and understand the process regarding digital supply chain with track-and-trace capabilities. Companies in the drug supply chain should be looking not only at the trace and track software but should also be looking very closely at choosing the right computational backend as well. As the healthcare business intelligence grows, so does its potential, creating a situation where choosing the right back-end can become as important as the front-end software decision. Furthermore, revisit FDA’s Guidance - Drug Supply Chain Security Act Implementation and understanding the fundamentals, including identification of suspect product and the notification process and much more.
 

Instructor Profile

David R. Dills, Independent Regulatory & Compliance Consultant, with an accomplished record has more than 22 years of hands-on experience with emphasis on Class I/II/III medical devices, In Vitro diagnostics, and pharmaceuticals in the areas of QA, Regulatory Affairs and Compliance.